Boston Scientific Corporation (BSX)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
BSX is trading near its usual valuation, near its historical support zone, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Cheap-looking, with quality flags (Yellow)
BSX trades at 18× earnings, below its own 5-year average of 61× and below similar healthcare companies we track (28×, 53 peers). Historically this has been on the cheaper side for the stock. Its free-cash-flow yield is about 5.5%. Growth is slower than its 3-year pace, which deserves some caution. Its current multiple sits around the 4th percentile of its own last five years — toward the low end of its own range.
Quality check: revenue growth has slowed to about 20% a year (3-year pace about 17%; analysts expect about 5% next year), while the multiple sits at the low end of its own history. That combination can mean the market is pricing a slower business rather than offering a bargain.
Price zones — Near its historical support zone (Green)
At $46.01, the stock is close to the lower end of its recent range. Over the past year BSX has traded between $41.39 and $105.65; its historical support zone sits near $45.66 and resistance near $58.09. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $41.39–$105.65 · 50-day average $45.66 · 200-day average $58.09
Money flow — No clear direction (Yellow)
Buying and selling volume in BSX have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 0.9× volume on down days over the last 30 sessions.
Dividends & company facts
BSX doesn't pay a dividend, and it issued more shares than it bought back in fiscal 2025. Its share count fell 0.6% over the past year.
- Shares, past year
- -0.6%
- Revenue, 12 months
- $21.0B
- Profit, 12 months
- $3.7B
- Employees
- 59,000
- CEO
- Michael F. Mahoney
- Headquarters
- Marlborough, MA
- Listed since
- 1992 · NYSE
About the company
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns.
Related stocks
一句话结论
BSX 估值接近其惯常水平，接近其历史支撑区，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 看似便宜，但有质量警示
BSX 目前的市盈率为 18×，低于其自身 5 年平均的 61×，并且低于我们追踪的同类Healthcare公司（28×，53 家）。从历史来看，这属于该股较便宜的一侧。其自由现金流收益率约为 5.5%。增速已慢于其 3 年的平均步伐，这一点值得留意。它当前的估值倍数大约位于自身过去五年分布的第 4 百分位——处于自身区间的偏低位置。
质量核对：营收增速已放缓至每年约 20%（3 年平均步伐约为 17%；分析师预期明年约为 5%），而估值倍数正处于自身历史的低位。这样的组合可能意味着市场在为一个增长更慢的业务定价，而不是在给出便宜的价格。
价格区间 — 接近其历史支撑区
目前价格为 $46.01，接近其近期区间的下沿。过去一年 BSX 的价格在 $41.39 到 $105.65 之间波动；其历史支撑区在 $45.66 附近，阻力区在 $58.09 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 方向不明确
BSX 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 0.9×。
股息与公司概况
BSX 不派发股息，并且在 2025 财年发行的股票多于回购的股票。其股数过去一年减少了 0.6%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.